Imexon Induces an Oxidative Endoplasmic Reticulum Stress Response in Pancreatic Cancer Cells

被引:24
作者
Sheveleva, Elena V. [1 ]
Landowski, Terry H. [1 ]
Samulitis, Betty K. [1 ]
Bartholomeusz, Geoffrey [2 ]
Powis, Garth [2 ]
Dorr, Robert T. [1 ]
机构
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA
[2] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Expt Therapeut, Houston, TX 77030 USA
关键词
MYELOMA CELLS; TUMOR-CELLS; GLUTATHIONE; APOPTOSIS; PROTEIN; CYTOTOXICITY; INHIBITION; RESISTANCE; INDUCTION; PATHWAY;
D O I
10.1158/1541-7786.MCR-11-0359
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oxidative protein folding in the endoplasmic reticulum (ER) requires strict regulation of redox homeostasis. Disruption of the lumenal redox balance induces an integrated ER stress response that is associated with reduced protein translation, increased chaperone activity, and ultimately cell death. Imexon is a small-molecule chemotherapeutic agent that has been shown to bind glutathione (GSH) and induce oxidative stress in tumor cells; however, the mechanism of cytotoxicity is not well understood. In this report, we investigate the effects of imexon on the integrated ER stress response in pancreatic carcinoma cells. Acute exposure to imexon induces an ER stress response characterized by accumulation of the oxidized form of the oxidoreductase Ero1 alpha, phosphorylation of eIF2 alpha, and inhibition of protein synthesis. An RNA interference chemosensitization screen identified the eukaryotic translation initiation factor eIF2B5 as a target that enhanced imexon-induced growth inhibition of MiaPaCa-2 pancreatic cancer cells, but did not significantly augment the effects of imexon on protein synthesis. Concurrent reduction of intracellular thiols with N-acetyl cysteine reversed imexon activity, however cotreatment with superoxide scavengers had no effect, suggesting thiol binding may be a primary component of the oxidative effects of imexon. Moreover, the data suggest that disruption of the redox balance in the ER is a potential therapeutic target. Mol Cancer Res; 10(3); 392-400. (C)2012 AACR.
引用
收藏
页码:392 / 400
页数:9
相关论文
共 30 条
[1]   Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer [J].
Azorsa, David O. ;
Gonzales, Irma M. ;
Basu, Gargi D. ;
Choudhary, Ashish ;
Arora, Shilpi ;
Bisanz, Kristen M. ;
Kiefer, Jeffrey A. ;
Henderson, Meredith C. ;
Trent, Jeffrey M. ;
Von Hoff, Daniel D. ;
Mousses, Spyro .
JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7
[2]   In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA [J].
Bartholomeusz, Geoffrey ;
Cherukuri, Paul ;
Kingston, John ;
Cognet, Laurent ;
Lemos, Robert, Jr. ;
Leeuw, Tonya K. ;
Gumbiner-Russo, Laura ;
Weisman, R. Bruce ;
Powis, Garth .
NANO RESEARCH, 2009, 2 (04) :279-291
[3]   A major fraction of endoplasmic reticulum-located glutathione is present as mixed disulfides with protein [J].
Bass, R ;
Ruddock, LW ;
Klappa, P ;
Freedman, RB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (07) :5257-5262
[4]   The CXXCXXC motif determines the folding, structure and stability of human Ero1-Lα [J].
Benham, AM ;
Cabibbo, A ;
Fassio, A ;
Bulleid, N ;
Sitia, R ;
Braakman, I .
EMBO JOURNAL, 2000, 19 (17) :4493-4502
[5]   A selective inhibitor-of eIF2α dephosphorylation protects cells from ER stress [J].
Boyce, M ;
Bryant, KF ;
Jousse, C ;
Long, K ;
Harding, HP ;
Scheuner, D ;
Kaufman, RJ ;
Ma, DW ;
Coen, DM ;
Ron, D ;
Yuan, JY .
SCIENCE, 2005, 307 (5711) :935-939
[6]   Glutathione is required to regulate the formation of native disulfide bonds within proteins entering the secretory pathway [J].
Chakravarthi, S ;
Bulleid, NJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) :39872-39879
[7]   A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer [J].
Cohen, Steven J. ;
Zalupski, Mark M. ;
Modiano, Manuel R. ;
Conkling, Paul ;
Patt, Yehuda Z. ;
Davis, Peg ;
Dorr, Robert T. ;
Boytim, Michelle L. ;
Hersh, Evan M. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) :287-294
[8]  
Dorr RT, 2005, J GASTROINTEST CANC, V36, P15, DOI 10.1385/IJGC:36:1:015
[9]   Phase I trial of imexon in patients with advanced malignancy [J].
Dragovich, Tomislav ;
Gordon, Michael ;
Mendelson, David ;
Wong, Lucas ;
Modiano, Manuel ;
Chow, H. H. Sherry ;
Samulitis, Betty ;
O'Day, Steven ;
Grenier, Kathryn ;
Hersh, Evan ;
Dorr, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1779-1784
[10]   Induction of mitochondrial changes in myeloma cells by imexon [J].
Dvorakova, K ;
Waltmire, CN ;
Payne, CM ;
Tome, ME ;
Briehl, MM ;
Dorr, RT .
BLOOD, 2001, 97 (11) :3544-3551